

SolidT, a platform technology for targeting solid tumors with safer and more effective cytotoxic T cells

Peleg Rider, Shahar Dotan, Diana Rasoulouniriana, Hana Shpilt, James Wooldridge, Yaron Carmi

Company name- Gilboa Therapeutics LTD * Website www.gilboa.bio * CEO name Barry Labinger

* Select a CATEGORY: Biotech/Pharma * • Evolving trends in cancer therapeutics

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Gilboa Tx is an Israeli biotech company which is proceeding toward phase I clinical trial for the treatment of solid tumors. Gilboa Tx technology is based on autologous engineered T cells, called SolidT, which are targeted to the tumors by a mAb against TAA. SolidT cells can be combined with any TAA-targeting mAb, therefore is a platform technology which can be used for different types of tumors. SolidT cells' cytotoxic response correlates to the TAA density on the targeted cell. Therefore, SolidT cells specifically target the tumor cells, which express high levels of TAA, while sparing the normal tissues, which express low levels. This allows SolidT cells to avoid off tumor cytotoxicity and premature exhaustion, resulting in a safer and more effective cell therapy.

o Core Technology What is the technology, its uniqueness, and its value proposition? Peripheral blood T cells are engineered with Gilboa's novel receptor, based on the highaffinity FcγRI scaffold, allowing T-cells to target different tumor cells using different targeting antibodies. This breakthrough technology overcomes limitations which are known to be associated with other cell therapies treating solid tumors, such as CAR-T cells.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Gilboa Tx is developing an extensive pipeline which include combining SolidT cells with trastuzumab for HER2 expressing solid tumors, with rituximab for CD20 expressing liquid tumors, and proceeding toward other indications using more novel antibodies against TAA.

o Business Strategy Briefly describe how the company will apply its core technology, generate shortterm and long-term revenues.

o The SolidT technology is an autologous cell therapy that will be developed as a therapeutic product in combination with relevant mAbs. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Completing process and analytical development, GMP manufacturing, and regulatory requirements in support of initiation in 2025 of a FIH clinical trial for the treatment of HER2- expressing solid tumors.